Drugs / Quetiapine fumarate XR
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00931723 Comparator | Jun 2009 → Nov 2010 | manic bipolar affective disorder | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quetiapine fumarate XR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00931723 ↗ |
| Route | Oral | “Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg.” NCT00931723 ↗ |